B+
Bull case
20%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
RCUS
Arcus BiosciencesDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-22
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+50.7
Score
AI commentary
News tone is mixed: the company reported encouraging ARC-20 data, while coverage describes a volatile post-readout share reaction and a subsequent offering. The packet's October 21 anchor is $19.10; a reliable full-session return and post-event analyst target revisions were not verified. Sentiment fields other than headline buzz are unmeasured placeholders, not observed readings. The negative deterministic directional prior and higher thesis-change score favor caution rather than treating historical trial comparisons as de-risking.
RankAlpha Sentiment Codex - 2026-10-22
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-23catalystPublic offering puts dilution and pricing in focusHigh impact
Arcus announced a common-stock offering on October 21. Its company-issued pricing announcement, syndicated by MarketScreener, states 14,285,715 shares at $17.50, with closing expected October 23, subject to conditions. The price is below the packet's October 21 $19.10 anchor. The separate SEC filing estimates September 30 cash and marketable securities at approximately $694 million, explicitly preliminary and unaudited. [#PR-2026-10-21][#8-K-2026-10-21][#SEC-8K-2026-10-21]
2026-12-31eventFirst-line PEAK-20 Phase 3 initiationHigh impact
Arcus says PEAK-20 remains on track to start by year-end 2026. The October 20 ARC-20 update reported 50% confirmed response in a 30-patient casdatifan-plus-zimberelimab cohort, but its comparisons with approved regimens are cross-trial, not randomized head-to-head evidence. Starting the trial would confirm execution, not efficacy. Company ARC-20 release [#PR-2026-10-20]
2027-12-31catalystPEAK-1 Phase 3 must validate second-line casdatifan combinationHigh impact
The October 20 ARC-20 release reported 14.5-month median progression-free survival in 43 patients receiving casdatifan plus cabozantinib; the approximately 10-month cabozantinib comparator is historical. The ongoing randomized PEAK-1 study is the decisive test of whether that apparent benefit replicates. No Phase 3 result date was established in the checked evidence. Company ARC-20 release [#PR-2026-10-20]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-22 • Updated nightlySource: Internal modelMethodology